clinical study, including due to patient safety concerns or lack of funding; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of any planned phase 2 clinical study of MST-188; the uncertainty of outcomes in ongoing and future studies of MST-188 and the risk that MST-188 may not demonstrat